Ulcerative colitis (UC)

Scotland
#Lymphoma #Marketing approval authorisation #NHS Scotland #Scottish Medicines Consortium (SMC) #Ulcerative colitis (UC) #Weight loss

Scottish Medicines Consortium advises on six new drugs

The Scottish Medicines Consortium (SMC), which advises on newly licensed medicines for use by NHS Scotland, has published advice on six medicines. 1. Tirzepatide (Mounjaro) was accepted for weight management in adults and is to be used alongside diet and exercise to help people lose weight. It was also given… Read More

#News #Regulatory

Business financing
#AltruBio #Antibody #Financing #Phase II trial #Ulcerative colitis (UC)

$225m to advance novel immune checkpoint enhancer programme

AltruBio has closed an oversubscribed Series B financing of up to $225 million, which will be used to advance the clinical development of the first-in-class, novel immune checkpoint enhancer (ICE) PSGL-1 agonist antibody, ALTB-268. The funds will be used to support ongoing and planned Phase II clinical trials in ulcerative… Read More

#Business & Investment #News

ulcerative colitis
#AI #BenevolentAI #Drug discovery #Ulcerative colitis (UC)

First patients dosed with an AI-derived target for ulcerative colitis 

BenevolentAI has dosed the first patients in Phase I first-in-human studies of its oral phosphodiesterase 10 (PDE10) inhibitor, BEN-8744, intended for the treatment of ulcerative colitis (UC). The topline data readout from this study is expected in the first quarter of 2024.  UC is a chronic disease… Read More

#News